Safety of urgent STA-MCA anastomosis after intravenous rt-PA treatment: a report of five cases and literature review

Acta Neurochir (Wien). 2018 Sep;160(9):1721-1727. doi: 10.1007/s00701-018-3576-y. Epub 2018 Jun 4.

Abstract

Background: Intravenous recombinant tissue-type plasminogen activator (rt-PA) with/without endovascular treatment is not as effective in atherosclerotic steno-occlusive acute ischemic stroke. Urgent superficial temporal artery-middle cerebral artery (STA-MCA) anastomosis is effective to some extent in progressing stroke, but the safety of STA-MCA anastomosis soon after rt-PA therapy is unknown. Our aim was to clarify the safety of STA-MCA anastomosis within 24 h after intravenous rt-PA.

Method: From 2005 to 2015, rt-PA was administered to 225 patients presenting with acute ischemic stroke according to the Japanese Stroke Guidelines, in our institution. Five patients underwent urgent STA-MCA anastomosis after rt-PA administration with or without endovascular recanalization. Clinical time course, surgical complications, and patients' prognosis were investigated.

Results: The average of patient age was 65.4 years (range 49-77 years); three patients had internal carotid artery occlusion, and two patients had middle cerebral artery occlusion. The median National Institutes of Health Stroke Scale score on admission was 12.4 (range 6-17 points) and operation occurred 10.6 h (range 5.3-23.6 h) after intravenous rt-PA administration. Hemostasis was achieved during standard STA-MCA anastomosis, and there were no hemorrhagic complications.

Conclusions: In our consecutive cases, urgent STA-MCA anastomosis after at least 5.3 h after intravenous rt-PA was performed safely without hemorrhagic complications.

Keywords: Complication; Emergent surgery; Progressing stroke; STA-MCA anastomosis; rt-PA.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Administration, Intravenous
  • Aged
  • Anastomosis, Surgical / adverse effects*
  • Anastomosis, Surgical / methods
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Infarction, Middle Cerebral Artery / surgery
  • Male
  • Middle Aged
  • Middle Cerebral Artery / surgery
  • Postoperative Complications / epidemiology*
  • Postoperative Complications / etiology
  • Temporal Arteries / surgery
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator